

**Suresh Surana & Associates LLP**  
Chartered Accountants  
308-309, A wing,  
Technopolis Knowledge Park,  
Mahakali Caves Road,  
Andheri (East), Mumbai- 400 093.  
Maharashtra, India.

**Bagaria & Co LLP**  
Chartered Accountants  
701 Stanford, S V Road,  
Andheri West,  
Mumbai – 400 058  
Maharashtra, India.

---

**Independent Auditors' Review Report on Quarterly Unaudited Standalone Financial Results pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.**

Review report to  
The Board of Directors of  
Piramal Enterprises Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Piramal Enterprises Limited ("the Company") for the quarter ended June 30, 2023 attached herewith (the "Statement") being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement which is the responsibility of the Company's management and approved by the Company's Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act 2013 ("the Act") as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial information is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under Section 133 of the Act, as amended read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement includes comparative unaudited restated financial results for the quarter ended June 30, 2022. The financial results for the quarter ended June 30, 2022 have been reviewed by predecessor auditor whose reports dated July 29, 2022, expressed an unmodified conclusion and opinion, on those financial results.




The above reviewed financial results have been restated pursuant to

- (a) the Company receiving the Certificate of Registration from the Reserve Bank of India, to carry on the business of non-banking financial company, accordingly it has prepared and presented its financial statements / results as per the format prescribed in Division III of Schedule III to Companies Act, 2013. The Statement includes comparative financial figures for the quarter ended June 30, 2022, which have been restated and reclassified to conform to the new format (Refer Note 3); and
- (b) the National Company Law Tribunal approval of Composite Scheme of Arrangement for demerger of Pharma undertaking and merger of PHL Fininvest Private Limited, an erstwhile wholly owned subsidiary, into the Company, effective from April 1, 2022, the comparative financial figures included in the Statement have been restated. (Refer Note 4 and 5)

Our conclusion on the Statement is not modified in respect of the above matter.


**For Suresh Surana & Associates LLP**  
**Chartered Accountants**  
Firm Reg. No. 121750W /W-100010

  
**Santosh Maller**  
Partner  
Membership No.: 143824  
UDIN: 23143824B6QQFN1209



Place: Mumbai  
Date: July 28, 2023

**For Bagaria & Co. LLP**  
**Chartered Accountants**  
Firm Reg No: 113447W / W-100019

  
**Rahul Bagaria**  
Partner  
Membership No.: 145377  
UDIN: 23145377B6RAFQ1359



Place: Mumbai  
Date: July 28, 2023

**Piramal Enterprises Limited**
**Statement of Standalone financial results for the Quarter ended 30 June 2023**
*(₹ in Crores)*

Particulars	Three months ended 30/06/2023	Three months ended 31/03/2023	Three months ended 30/06/2022	Previous year ended 31/03/2023
	(Unaudited)	(Refer Note 13)	(Unaudited, Restated)*	(Audited)
<b>Revenue from operations</b>				
Interest income	371.78	418.29	460.59	1,736.47
Dividend income	76.20	91.69	0.04	140.34
Fees and commission income	0.58	2.89	3.81	9.83
Net gain/(loss) on fair value changes (Refer Notes 6 & 7)	733.07	(332.34)	63.29	41.14
Other operating income (Refer Note 6)	12.75	-	-	2,857.44
<b>Revenue from operations</b>	<b>1,194.38</b>	<b>180.53</b>	<b>527.73</b>	<b>4,785.22</b>
Other income	7.96	8.52	11.87	51.91
<b>Total Income</b>	<b>1,202.34</b>	<b>189.05</b>	<b>539.60</b>	<b>4,837.13</b>
<b>Expenses</b>				
Finance cost	201.40	166.78	230.13	711.77
Fees and commission expenses	1.15	2.04	3.32	18.09
Net loss on derecognition of financial instruments under amortised cost category (Refer Note 9)	127.07	235.69	-	1,371.31
Impairment on financial instruments	(44.69)	(277.31)	117.90	3.42
Employee benefits expenses	33.22	9.82	18.68	83.86
Depreciation, amortisation and impairment	2.41	2.13	5.52	23.00
Other expenses (Refer Note 7)	152.75	60.38	53.19	227.00
<b>Total expenses</b>	<b>473.31</b>	<b>199.53</b>	<b>428.74</b>	<b>2,438.45</b>
<b>Profit / (loss) before exceptional items and tax</b>	<b>729.03</b>	<b>(10.48)</b>	<b>110.86</b>	<b>2,398.68</b>
Exceptional items gain/(loss) net of tax (Refer Notes 4 & 5)	-	-	11,459.96	11,912.22
<b>Profit / (loss) before tax</b>	<b>729.03</b>	<b>(10.48)</b>	<b>11,570.82</b>	<b>14,310.90</b>
<b>Tax expense</b>				
Current tax	74.56	-	17.63	-
Deferred tax (credit)/charge	77.43	46.40	4.66	(22.40)
	<b>151.99</b>	<b>46.40</b>	<b>22.29</b>	<b>(22.40)</b>
<b>Profit / (loss) for the period / year</b>	<b>577.04</b>	<b>(56.88)</b>	<b>11,548.53</b>	<b>14,333.30</b>
<b>Other comprehensive income</b>				
(A) Items that will not be reclassified to profit or loss				
Changes in fair values of equity instruments through OCI (Refer Note 6)	(6.91)	22.31	(26.90)	108.14
Remeasurement of the defined benefit plan	-	(0.76)	0.08	1.37
Income tax relating to items that will not be reclassified to profit or loss	(12.84)	(5.43)	12.67	36.31
(B) Items that will be reclassified to profit or loss				
Changes in fair values of debt instruments through OCI	0.61	(4.99)	-	(0.27)
Income tax relating to items that will be reclassified to profit or loss	-	1.16	-	0.02
<b>Total other comprehensive income net of tax</b>	<b>(19.14)</b>	<b>12.29</b>	<b>(14.15)</b>	<b>145.57</b>
<b>Total comprehensive income for the period / year</b>	<b>557.90</b>	<b>(44.59)</b>	<b>11,534.38</b>	<b>14,478.87</b>
Paid-up Equity Share Capital (Face Value of ₹ 2/-each)				47.73
Other Equity				23,986.73
<b>Earning per share</b>				
Basic (₹)	not annualised	not annualised	not annualised	
Diluted (₹)@	24.18	(2.38)	483.88	600.56
	24.10	(2.38)	483.83	598.58

\* Refer Notes 3,4 & 5 to the accompanying standalone results

@ In view of loss for the quarter ended 31/03/2023, options which are anti-dilutive have been ignored in the calculation of diluted earnings per share.


**Piramal Enterprises Limited**

Piramal Ananta Agastya Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai - 400 070 | CIN: L24110MH1947PLC005719

[www.piramal.com](http://www.piramal.com)




**Statement of Standalone financial results for the Quarter ended 30 June 2023**

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of Piramal Enterprises Limited ("the Company") in its meeting held on 28 July 2023 and subjected to limited review by joint auditors, pursuant to Regulation 33 and Regulation 52 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The Board of Directors at its meeting held on 28 July 2023, approved buyback of equity shares of the company of upto 1,40,00,000 number of Equity Shares of face value of ₹ 2/- each representing 5.87% of the pre-buyback fully paid up equity shares at a price of ₹1,250 per share for an aggregating to ₹ 1,750 crores, through the tender offer route.
- Up to the quarter ended 30 June 2022, the Company used to prepare and present financial statements/ results as per the format prescribed in Division II of Schedule III to Companies Act, 2013. On 26 July 2022, the Company has received Certificate of Registration to carry on the business of Non-Banking Financial Institution. Accordingly, the Company has prepared and presented financial statements as per the format prescribed in Division III of Schedule III to Companies Act, 2013. The figures for the quarter ended 30 June 2022 in the above results had been restated and reclassified to conform to the new format.
- The composite scheme of arrangement ("the Scheme") for demerger of Pharma undertaking and merger of PHL Fininvest Private Limited, a wholly owned subsidiary company, into the Company was approved by the Hon'ble National Company Law Tribunal on 12 August 2022. Accordingly, the Scheme became operative from Appointed date i.e. 1 April 2022. Consequently, the previously issued standalone financial results for quarter ended 30 June 2022 have been restated to give impact to the Scheme.

- In accordance with the above mentioned composite scheme of arrangement, in the previous period the Company has given effect to accounting as follows:

**I) Demerger of Pharma undertaking:-**

During the previous year, all assets and liabilities pertaining to demerged Pharma undertaking have been classified as non-cash assets held for transfer to Piramal Pharma Limited / shareholders as on 1 April 2022 being the appointed date. The difference between book values of the assets and liabilities transferred is recognised as gains in Profit and loss account amounting to ₹ 11,459.96 crores as per the requirements of Appendix A to Ind AS 10. At the date of approval of the Scheme, the liability was subsequently remeasured resulting in remeasurement gain of ₹ 759.76 crores. The corresponding aggregate charge was recognised in retained earnings (reserve) as per the requirements of the aforesaid Ind AS.

The nature of the gain (including remeasurement gain) being non-recurring in nature was classified as "exceptional items" by the Company.

**(II) Merger of PHL Fininvest Private Limited :-**

During the previous year All assets and liabilities of PHL Fininvest Private Limited have been recorded at book values as appearing in the financial statement after eliminating all inter-company transactions and balances. All prior period comparative information was restated as per the requirements of Appendix A to Ind AS 103.

The following table represents reported numbers and restated numbers based on above paragraph.

(₹ In Crores)


Particulars	Quarter ended	
	30 June 2022	30 June 2022
	Restated (Refer Notes 3 & 4)	Reported (Refer Notes 3 & 4)
Total Income	539.60	556.04
Profit after tax	11,548.53	28.08

(iii) Costs incidental / consequential to the arrangement aggregating to ₹ 307.46 crores (net of tax) incurred by the Company was considered as exceptional items being non-recurring in nature.

- During the previous year, pursuant to Composite Scheme of Arrangement and Amalgamation in Shriram group, the Company had received shares of Shriram Finance Limited (SFL), Shriram LI Holdings Private Limited (SLIH), Shriram GI Holdings Private Limited (SGIH) and Shriram Investment Holdings Limited (SIHL) against the shares of Shriram City Union Finance Limited (SCUF) and Shriram Business Consultancy Private Limited (Shrilekha). These shares have been initially recognised as per the requirement of Ind AS 109 as follows:
  - Shares received against investment in SCUF resulted in gain of ₹ 172.10 crores accounted in other comprehensive income.
  - Shares received against investment in Shrilekha resulted in gain of ₹ 2,857.44 crores accounted in profit and loss.
 Further, during the quarter ended 30 June 2023, the Company had sold its entire stake in Shriram Finance Limited for a net consideration of ₹ 4,788.58 crores resulting in profit of ₹ 854.68 crores which has been recorded under "Net gain / (loss) on fair value changes".
- Based on review of internal and external factors, the management has reassessed the assumptions, strategy and business model pertaining to its investments in Real Estate fund management business. Accordingly, the Company has recognised impairment provision of ₹ 108.26 crores, recorded under "Other expenses" and a fair valuation loss amounting to ₹ 61.01 crores, recorded under "Net gain/(loss) on fair value changes" during the quarter ended 30 June 2023.



*Nishi Anand*



- 8 All the secured non-convertible debentures of the Company are fully secured by way of first pari-passu charge by hypothecation over the movable assets and specific charge over the certain receivable and investments. Further, the Company has at all times for the non-convertible debentures Issued, maintained security cover as stated in the respective Information memorandum which is sufficient to discharge the principal amount, Interest accrued thereon and such other sums as mentioned therein.
- 9 The Company has recognised a prudential write off in compliance to Ind AS 109 amounting to ₹ 118.33 crores during the quarter (included in "Net loss on derecognition of financial Instruments under amortised cost category" in the financial results). The same has been approved by the Board of Directors.
- 10 The Company is primarily engaged in the business of financing and accordingly there are no separate reportable segmental information as per Ind AS 108.
- 11 Disclosures pursuant to RBI Notification - RBI/DOR/2021-22/86 DOR.STR.REC.51/21.04.048/2021-2.2 dated 24 September 2021

(a) Details of loans (not in default) acquired through assignment for the quarter ended 30 June 2023:

Amount of loans acquired through assignment	₹ 966.97 crores
Retention of beneficial economic interest	Note 1
Weighted average residual maturity	32 months
Weighted average holding period	17 months
Coverage of tangible security	Note 2
Rating-wise distribution of rated loans	Unrated

**Note 1**

For Deals executed within the group, Retention of beneficial economic interest is Nil  
For External Deals, Retention of beneficial economic interest is 10%

**Note 2**

For Housing Loan/Loan Against Property/Mid Market Lending 100% cover  
For Unsecured Loans - NIL

(b) The Company has not transferred any loan (not in default) through assignment during the quarter ended 30 June 2023.

(c) The Company has not transferred any stressed loan during the quarter ended 30 June 2023.

(d) The Company has not acquired any stressed loan during the quarter ended 30 June 2023.

(e) Details of ratings on Security Receipts (SRs) outstanding as on June 30, 2023.

(₹ In Crores)			
Rating	Rating Agency	Recovery Rating	Amount outstanding
RR1	Infometrics Valuation and Rating Pvt Ltd	100% - 150%	446.34
Unrated*			67.18
	<b>Grand Total</b>		<b>513.52</b>

\* Pursuant to the Reserve Bank of India circular RBI/2021-22/154 DOR.SIG.FIN.REC 84/26.03.001/2021-22 dated February 10, 22, the security receipts issued to the Company by the Asset Reconstruction Company (ARC) towards consideration for transfer of stressed loans have not been rated by the ARC since the prescribed time period of six months has not elapsed from the date of acquisition of loans by the ARC.

- 12 Disclosure in terms of Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the quarter ended 30 June 2023 is attached as per Annexure 1.
- 13 The figures for the last quarter of previous financial year (restated) are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of third quarter of the previous financial year which were subjected to limited review by joint statutory auditors.
- 14 Previous period/ year's figures have been regrouped/reclassified wherever necessary, to conform to current period classification.

For Piramal Enterprises Limited



Ajay G. Piramal  
Chairman

28 July 2023, Mumbai



**Statement of Standalone financial results for the Quarter ended 30 June 2023**
**Annexure 1**
**Disclosures in terms of Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sr. No.	Particulars	For the quarter ended 30/06/2023
1	Debt - Equity ratio [Debt Securities + Borrowings (other than debt securities) + Deposit + Subordinated debt] / Net Worth	0.28
2	Net Worth (₹ in Crores)	20,717.53
3	Net Profit after tax (₹ in Crores)	577.04
4	Earning per share	
	Basic (₹)	24.18
	Diluted (₹)	24.10
5	Total debts to total assets ratio [Debt securities+Borrowings (other than debt securities)+Deposits+Subordinated debts] / Total Assets	19.06%
6	Net profit margin [Profit After Tax / Total Income]	47.99%
7	Sector specific equivalent ratio as applicable	
	(A) Gross NPA (Stage 3 assets gross) ratio	4.88%
	(B) Net NPA (Stage 3 assets net) ratio	2.18%

**Note:** Debt service coverage ratio, Interest service coverage ratio, Current ratio, Long term debt to working capital, Bad debts to Account receivable ratio, Current liability ratio, Debtors turnover, Inventory turnover, Operating margin are not applicable to the Company.